# Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

> **NCT06630130** · PHASE2 · RECRUITING · sponsor: **Jeeyun Lee** · enrollment: 50 (estimated)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DRUG:** Trastuzumab deruxtecan
- **DRUG:** Capecitabine
- **DRUG:** Rilvegostomig

## Key facts

- **NCT ID:** NCT06630130
- **Lead sponsor:** Jeeyun Lee
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-22
- **Primary completion:** 2028-10-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06630130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06630130, "Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06630130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*